European Journal of Cancer最新文献

{"title":"The impact of occult and minimal residual lymph node metastases after neoadjuvant chemotherapy on the outcomes of early breast cancer patients","authors":"W.S. Chung , C.C. Yu , T.M. Ko","doi":"10.1016/j.ejca.2026.116350","DOIUrl":"10.1016/j.ejca.2026.116350","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116350"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147539272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell systems network and machine learning dissection of ferroptosis in recurrent glioblastoma highlights astrocytic ZFP36 as a therapeutic hub for network medicine repurposing","authors":"Mahima Kishinani ,&nbsp;Manoj Girish ,&nbsp;Swati Sinha ,&nbsp;Sainitin Donakonda","doi":"10.1016/j.ejca.2026.116591","DOIUrl":"10.1016/j.ejca.2026.116591","url":null,"abstract":"<div><h3>Background</h3><div>Recurrent glioblastoma multiforme (rGBM) arises after conventional treatment strategies for primary GBM (pGBM) fail, leading to a more aggressive, therapy-resistant phenotype, with an overall survival of ∼9 months. Current treatment strategies rely on apoptosis and are frequently ineffective. Moreover, ferroptosis has recently been identified as a potential alternative cell death pathway in glioma. Therefore, this study investigated the mechanisms and therapeutic potential of ferroptosis in rGBM at the glial cell type level.</div></div><div><h3>Methods</h3><div>We analyzed a publicly available single-cell datasets to profile tumor-specific glial cells and assess ferroptosis-related perturbations in rGBM versus pGBM. Network-based machine learning analyses were employed to highlight key ferroptosis drivers in rGBM. Finally, we employed network medicine, molecular docking, and molecular dynamics simulations to identify a potential therapeutic target.</div></div><div><h3>Results</h3><div>Network-based ranking captured a ferroptosis suppressor, <em>ZFP36</em>, in astrocytes, and pathway enrichment analysis of its interaction subnetwork revealed MAPK and metabolic pathways, supporting its role in tumor growth. Network medicine identified drugs targeting ZFP36, with proximity analysis showing that drug-binding MAP kinases are closer to ZFP36, suggesting that these drugs may also modulate ZFP36 activity. Furthermore, similarity analyses with known ferroptosis inducers identified 4-Phenoxy-N-(Pyridin-2-Ylmethyl)Benzamide as a potential drug target for ZFP36. Molecular docking and dynamics simulations showed that the drug binds to the druggable binding site of ZFP36, modulating its structure.</div></div><div><h3>Conclusion</h3><div>The findings of this study suggest that modulating ferroptosis suppressor ZFP36 could promote cell death in rGBM via the ferroptosis pathway.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116591"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system","authors":"Quentin Samaran ,&nbsp;Thomas Bettuzzi ,&nbsp;Emilie Sbidian","doi":"10.1016/j.ejca.2026.116585","DOIUrl":"10.1016/j.ejca.2026.116585","url":null,"abstract":"<div><h3>Background</h3><div>Anti-PD-1 agents have demonstrated meaningful response rates in single-arm trials for advanced cutaneous squamous cell carcinoma (acSCC). However, no randomised or large-scale real-world studies have directly compared their effectiveness with cetuximab, used alone or in combination with chemotherapy, which has long been used off-label as first-line systemic therapy in this setting. This study compared survival outcomes with first-line anti-PD-1 therapy versus cetuximab using French nationwide data.</div></div><div><h3>Methods</h3><div>We conducted a retrospective nationwide population-based cohort study of the French national health data system (SNDS). Adults with acSCC initiating first-line systemic therapy between 2017 and 2023 were included; those with alternative diagnoses or prior systemic therapy were excluded. The primary endpoint was overall survival (OS); the secondary endpoint was switch-free survival (SFS), used as a proxy for progression-free survival. Cox models with stabilised inverse probability of treatment weighting were used. Predefined subgroup and sensitivity analyses were performed.</div></div><div><h3>Results</h3><div>Among 3006 patients (median age, 80 years; 74 % men), 2115 received anti-PD-1 (587 cemiplimab, 1118 pembrolizumab, 410 nivolumab) and 891 cetuximab. Median OS was 26 months with anti-PD-1 versus 14 with cetuximab (weighted HR, 0.79; 95 % CI, 0.69–0.90; p &lt; 0.001). Median SFS was 22 versus 8 months (weighted HR, 0.59; 95 % CI, 0.52–0.67; p &lt; 0.0001). Results were consistent across age, sex, and anti-PD-1 subgroups.</div></div><div><h3>Conclusions</h3><div>First-line anti-PD-1 therapy significantly improved overall and switch-free survival compared with cetuximab, used alone or in combination with chemotherapy. These findings provide robust real-world evidence supporting anti-PD-1 agents as the preferred first-line systemic treatment for acSCC in dermatologic oncology practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116585"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of gut microbiota on hepatocellular carcinoma: Pathogenesis, diagnosis, prognosis, and therapeutic prospective","authors":"Qunwei Chen ,&nbsp;Xinyan Feng ,&nbsp;Jingxian Wang ,&nbsp;Huilin Zhu ,&nbsp;Zhiyuan Bo ,&nbsp;Binbin Wang ,&nbsp;Zhengxiao Zhao","doi":"10.1016/j.ejca.2026.116581","DOIUrl":"10.1016/j.ejca.2026.116581","url":null,"abstract":"<div><div>Advances in sequencing technology have elucidated the complex role of the gut microbiota in hepatocellular carcinoma (HCC). Communication between the gut and the liver occurs via the gut-liver axis, and dysbiosis of the gut microbiota has been implicated in both the promotion and suppression of HCC. Furthermore, through interactions with host metabolism and immune system, the gut microbiota significantly influences treatment responses and prognostic outcomes of HCC. Despite progress in therapeutic strategies, clinical efficacy remains suboptimal, underscoring the need for a deeper understanding of the gut microbiota's role. This review highlights the potential of gut microbiota as novel biomarkers for the diagnosis and prognostic prediction of HCC, and explores its therapeutic implications. We summarize current insights into the molecular mechanisms underlying the gut microbiota-HCC interplay, and emphasize the relationship between gut microbiota and the efficacy of various treatments, including surgery, chemotherapy, radiotherapy, immunotherapy, and targeted agents. Microbiome-targeting interventions like probiotics, fecal microbiota transplantation (FMT), and dietary changes as emerging adjuvant strategies are also discussed in detail to provide potential resources for advancing translational hepatology. Although challenges remain, this review aims to provide valuable perspectives for developing individualized therapeutic strategies in HCC management.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116581"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC","authors":"Goki Suda,&nbsp;Masatsugu Ohara,&nbsp;Masato Nakai,&nbsp;Takuya Sho,&nbsp;Naoya Sakamoto","doi":"10.1016/j.ejca.2026.116580","DOIUrl":"10.1016/j.ejca.2026.116580","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116580"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study","authors":"Sidsel Pedersen ,&nbsp;Lotte B. Colmorn ,&nbsp;Eva Ellebaek ,&nbsp;Stine Gry Kristensen ,&nbsp;Christina Ruhlmann ,&nbsp;Troels Holz Borch ,&nbsp;Marco Donia ,&nbsp;Jens Fedder ,&nbsp;Kirsten T. Macklon ,&nbsp;Inge Marie Svane","doi":"10.1016/j.ejca.2026.116584","DOIUrl":"10.1016/j.ejca.2026.116584","url":null,"abstract":"<div><h3>Introduction</h3><div>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment and are increasingly used in the adjuvant and neoadjuvant setting for malignancies such as melanoma, which often affect younger adults. With improving survival, concerns about long-term safety, including potential effects on fertility, are growing.</div></div><div><h3>Methods</h3><div>We conducted a national, multicenter, prospective observational study of female patients &lt; 45 years treated with adjuvant anti-PD-1 therapy for resectable stage III–IV melanoma from 2018 to 2024. Ovarian function was assessed at baseline and at 3, 6, 12, and 18 months after treatment initiation. Each visit included transvaginal ultrasound for antral follicle count (AFC) and serum analysis of anti-Müllerian hormone (AMH), estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and inhibin-B.</div></div><div><h3>Results</h3><div>Seventeen female patients were enrolled (mean age 28.9 years, range 17–38). Median follow-up was 5.1 years. Ovarian morphology and AFC remained normal and stable at all time points. No decline in AMH was observed during or after treatment. FSH, LH, estradiol, progesterone, and inhibin-B levels fluctuated within physiological ranges consistent with normal menstrual cycling. After completing adjuvant therapy, five patients had at least one child, and one was pregnant at data cut-off. Two patients developed endocrine immune-related toxicity (type 1 diabetes and hypophysitis); both conceived post-treatment.</div></div><div><h3>Discussion</h3><div>This prospective evaluation of ovarian function during and after adjuvant anti-PD-1 therapy in melanoma found no evidence of treatment-related ovarian insufficiency, including in patients with endocrine toxicities. These findings are important for counseling young patients receiving adjuvant therapy who may wish to conceive in the future.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116584"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group","authors":"Eva Kalfala ,&nbsp;Alexandra Meurgey ,&nbsp;Clémence Hénon ,&nbsp;Mehdi Brahmi ,&nbsp;Maud Toulmonde ,&nbsp;Pascaline Boudou-Rouquette ,&nbsp;Emmanuelle Bompas ,&nbsp;Nicolas Penel ,&nbsp;Nelly Firmin ,&nbsp;Florence Duffaud ,&nbsp;Isabelle Desmoulins ,&nbsp;Agnès Ducoulombier ,&nbsp;Mathilde Cancel ,&nbsp;Sarah Watson ,&nbsp;Mohamed Khettab ,&nbsp;Tiffany Darbas ,&nbsp;Anne Kieffer ,&nbsp;Cécile Guillemet ,&nbsp;Justine Gantzer ,&nbsp;Christophe Perrin ,&nbsp;Armelle Dufresne","doi":"10.1016/j.ejca.2026.116590","DOIUrl":"10.1016/j.ejca.2026.116590","url":null,"abstract":"<div><h3>Background</h3><div>Alveolar soft part sarcoma (ASPS) is an ultra-rare sarcoma with limited chemotherapy sensitivity affecting mostly young patients. Tyrosine kinase inhibitors (TKIs) and immunotherapy are therapeutic advances with promising results in this disease. The aim of this study was to describe the characteristics, management and survival of patients with ASPS in France.</div></div><div><h3>Patients and Methods</h3><div>The French NETSARC+ database was screened for all adult patients with ASPS managed in French sarcoma centers between 2010 and 2023.</div></div><div><h3>Results</h3><div>Sixty-four patients from 18 centers were analyzed. The 5-year overall survival (OS) of the entire cohort was 87.3 % (95 % CI, 75.0–93.8 %). Fifty-six percent of patients had localized tumors at diagnosis; all were treated surgically, and 47 % received perioperative radiotherapy. With a median follow-up of 91 months, their 5-year OS was 96.3 % (95 % CI, 76.5–99.5 %). Half of the patients experienced metastatic recurrence with a median metastasis-free survival of 87.9 months (95 % CI, 29.6-NE). In patients with metastases, the first-line systemic treatment yielded an overall response rate of 7 %, 26 %, and 40 % for chemotherapy, TKIs, and immunotherapy, respectively. The 5-year OS after metastasis diagnosis was 67.7 % (95 % CI: 50.5–80.0 %).</div></div><div><h3>Conclusion</h3><div>Our cohort reinforces existing data on clinical characteristics and demonstrated prolonged survival in both localized and metastatic stages. Among systemic treatments, immunotherapy achieved the highest response rates. We confirmed that ASPS may follow an indolent course in some cases and highlighted recent advances in its management, driven by standardized local treatments in reference centers and innovative systemic therapies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116590"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands” [Eur J Cancer 205 (2024)114125]","authors":"V.D. de Jager ,&nbsp;B.N. Cajiao Garcia ,&nbsp;C.C.H.J. Kuijpers ,&nbsp;G.H. de Bock ,&nbsp;W.J. Maas ,&nbsp;W. Timens ,&nbsp;L.C. van Kempen ,&nbsp;A.J. van der Wekken ,&nbsp;E. Schuuring ,&nbsp;S.M. Willems","doi":"10.1016/j.ejca.2026.116597","DOIUrl":"10.1016/j.ejca.2026.116597","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116597"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach","authors":"Jeong Ha Lee ,&nbsp;Nalee Kim ,&nbsp;Jeong Il Yu ,&nbsp;Hee Chul Park ,&nbsp;Sungkoo Cho ,&nbsp;Byeong Geun Song ,&nbsp;Myung Ji Goh ,&nbsp;Wonseok Kang ,&nbsp;Dong Hyun Sinn ,&nbsp;Geum-Youn Gwak ,&nbsp;Joon Hyeok Lee ,&nbsp;Yong-Han Paik ,&nbsp;Moon Seok Choi ,&nbsp;Minsuk Kwon ,&nbsp;Jung Yong Hong ,&nbsp;Gyu-Seong Choi ,&nbsp;Woo Kyoung Jeong ,&nbsp;Min Woo Lee ,&nbsp;Dong Ho Hyun ,&nbsp;Sang Yun Ha","doi":"10.1016/j.ejca.2026.116593","DOIUrl":"10.1016/j.ejca.2026.116593","url":null,"abstract":"<div><h3>Background</h3><div>Since December 2015, the Proton Beam Therapy (PBT) center at Samsung Medical Center has treated 2000 cases involving 1823 patients with HCC who were ineligible for Barcelona Clinic Liver Cancer (BCLC) guideline-recommended standard treatments. This study evaluated clinical outcomes and explored the potential role of PBT as an alternative local modality.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed patients with HCC treated with PBT. The primary endpoint was freedom from local progression (FFLP), and the secondary endpoints were overall survival (OS) and toxicity.</div></div><div><h3>Results</h3><div>The annual number of PBT cases increased, among all cases, 93.0 % targeted intrahepatic lesions, while 7.0 % targeted extrahepatic lesions. FFLP was evaluated in intrahepatic cases with a median follow-up of 19.5 months (interquartile range [IQR], 8.5–39.7). The 2-year FFLP exceeded 90 % across the treatment periods without significant differences (P = 0.51). According to the BCLC stages (0, A, B, and C), the 2-year FFLP rates were 95.5 %, 93.9 %, 98.5 %, and 87.6 %, respectively, and the 3-year FFLP rates were 91.1 %, 91.3 %, 95.0 %, and 83.3 %, respectively (P &lt; 0.001). The median OS follow-up was 18.7 months (IQR 7.9–38.6). The 3-year OS rates were 81.1 % in BCLC stage 0; 65.5 %, stage A; 45.5 %, stage B; and 37.2 %, stage C, respectively (P &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>This large, single-center study demonstrated that PBT provided favorable local control and survival outcomes, supporting its role as a promising local ablative modality to address the unmet therapeutic needs in HCC.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116593"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of elinzanetant for the treatment of vasomotor symptoms in women with breast cancer: subgroup analysis of the OASIS-4 trial by type of endocrine therapy","authors":"F. Cardoso ,&nbsp;D. Brennan ,&nbsp;T. Simoncini ,&nbsp;L. Wahyudi ,&nbsp;K. Laapas ,&nbsp;C. Seitz","doi":"10.1016/j.ejca.2026.116302","DOIUrl":"10.1016/j.ejca.2026.116302","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"237 ","pages":"Article 116302"},"PeriodicalIF":7.1,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147544872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}